Gastritis: Symptoms, Diagnosis, Treatment & Red Flags

Gastritis describes inflammatory infiltrates in the gastric mucosa with corresponding clinical–histologic patterns ranging from minimal erythema to erosive, hemorrhagic injury. It is not synonymous with dyspepsia: plenty of people harbor H. pylori infection without meaningful symptoms, while others feel miserable despite mild endoscopic findings.

Pathophysiology reflects a stress–defense mismatch. Aggressors include acid–peptic digest, direct toxin or drug injury, ischemia, and immune-mediated attack on parietal cells. Defense hinges on mucus–bicarbonate, epithelial restitution, mucosal blood flow, and prostaglandin-supported barrier maintenance—NSAIDs erode that prostaglandin cushion even when pain control seems appropriate on paper.

Chronic phenotypes may march toward atrophy or intestinal metaplasia in susceptible hosts, amplifying long-term stomach cancer surveillance conversations when risk stratification flags premalignant change.

Endoscopy and histology supply the granularity that symptom labels lack. The table condenses how bedside teams translate pathologic patterns into monitoring emphasis.

↔On a small screen, swipe or scroll sideways to see the full table.

Presentation spans silent histologic inflammation through visceral burning, early satiety, bloating, and post-prandial discomfort. Upper abdominal pain localized to the epigastrium is common yet nonspecific. Nausea and vomiting appear with pronounced mucosal irritation or concurrent ileus. Blood loss may be occult—fatigue from anemia—or florid with blood in vomit and tarry black stool.

Populations that skew atypical

Older adults may report weakness or delirium without classic pain; NSAID ulcers can present with syncope from hypotension; pregnant patients overlap physiologic dyspepsia with pathologic gastritis—tie escalation to objective vitals, laboratory trends, and obstetric input.

Infectious: H. pylori tops the list worldwide; consider gastroenteritis–like prodromes only when diarrhea or shedding fits acute self-limited infection rather than isolated gastric mucosal disease.

Mechanical chemical injury: NSAIDs (including low-dose aspirin), alcohol, cocaine, bile reflux.

Systemic critical illness: Shock, burns, trauma, and major surgery fuel stress gastropathy; acid suppression strategy follows unit protocol and risk scoring.

Autoimmune and hypersensitivity: Autoimmune gastritis, eosinophilic gastritis, rare drug reactions.

Infiltrative / malabsorptive neighbors: Maintain awareness of celiac disease when diarrhea, weight loss, and iron deficiency cluster, even if stomach symptoms are mild.

Clinical assessment

Map alarm features, medication and alcohol exposure, prior eradication attempts, anticoagulation, and cardiac risk. Quantify bleeding: orthostasis, postural BP, stool color triage, anticoagulant timing.

Laboratory investigations

• Complete blood count for anemia or thrombocytopenia suggesting acute consumption.
• Comprehensive metabolic panel for renal dosing of PPIs, electrolyte shifts, and albumin context.
• Non-invasive Helicobacter pylori testing after appropriate proton pump inhibitor, bismuth, and antibiotic withholding windows.

Endoscopy and histology

Upper endoscopy (EGD) with biopsy clarifies erosive severity, excludes malignancy, grades atrophy or intestinal metaplasia, and captures H. pylori–equivalent organisms on special stains when rapid urease testing is equivocal.

↔On a small screen, swipe or scroll sideways to see the full table.

Treat drivers before chasing symptom layers alone. Eradication regimens follow local resistance patterns; North American guidance increasingly favors optimized bismuth quadruple therapy when susceptibility is unknown, with structured salvage sequences after failure—prescribers select exact combinations and durations.

Acid suppression

Proton pump inhibitors such as omeprazole remain first-line symptom control for many erosive patterns. Famotidine and other histamine blockers suit step-down, pregnancy discussions per formulary, or adjuvant therapy when PPI dose minimization is the goal.

Eradication therapy components (illustrative)

Guideline-era regimens pair high-dose acid suppression with antibiotics; amoxicillin remains a common backbone when not contraindicated. Nurses watch diarrhea, rash, pill burden, drug–drug interactions (warfarin, clopidogrel, QT-prolonging agents), and adherence to the full course even when symptoms vanish early.

Supportive and withdrawal measures

• Stop offending NSAIDs or swap to gastro-sparing strategies with prescriber partnership.
• Treat alcohol use disorder pathways when ethanol drives recurrent erosions.
• Replace iron or B12 when autoimmune or severe chronic atrophy creates malabsorption.

Use a visit sequence that mirrors outpatient and ward cadence: confirm alarm status → stabilize bleeding if present → test for H. pylori when appropriate → start timed eradication → schedule post-therapy test-of-cure → revisit indications for continued PPI.

• Monitoring: Daily weights and orthostatic vitals during bleeds; serial hemoglobin every 6–12 h while unstable, then per response; type-and-screen readiness for large transfusions.
• Medication safety: Reconcile high-risk drugs (anticoagulants, dual antiplatelet therapy, NSAIDs hidden in OTC cold remedies).
• Failure patterns: Persistent pain beyond 8 weeks of compliant therapy, recurrent anemia, or repeat bleeding mandates endoscopy escalation.
• Documentation: Capture melena quantity, hematemesis appearance (coffee-ground versus fresh), time of last anticoagulant dose, and shared decision discussions on risk.

Bedside monitoring checklist

• Heart rate and blood pressure trends with position changes
• Urine output and lactate when shock suspected
• NG aspirate color and volume when tubes are in situ per protocol
• Mental status—especially older adults with occult bleeding

Clinical decision flow (brief)

1. Unstable bleed → resuscitation + urgent gastroenterology/surgery activation.
2. Stable without alarms → non-invasive H. pylori testing when indicated.
3. Alarms → direct endoscopy referral rather than prolonged empiric PPI alone.
4. Post-eradication → schedule test-of-cure with documented PPI hold windows.

• Upper gastrointestinal hemorrhage requiring transfusion, endoscopic therapy, or surgery.
• Perforation or penetration into adjacent organs with peritonitis.
• Gastric outlet obstruction from chronic pyloric edema or scarring.
• Iron deficiency or vitamin B12 deficiency from chronic blood loss or autoimmune atrophy.
• Progression along a neoplastic pathway when chronic atrophic gastritis and intestinal metaplasia go undetected.

Clinician-facing prevention means NSAID stewardship, alcohol screening and brief intervention, early H. pylori eradication before decades of mucosal injury accrue, and targeted surveillance only where guidelines support endoscopy intervals—not blanket screening endoscopy for every dyspeptic patient.

When the offending agent departs—successful eradication, NSAID withdrawal, alcohol reduction—many people experience durable improvement. Chronic atrophic phenotypes may stabilize yet still warrant micronutrient follow-up. Failure to cure H. pylori or continued mucosal injury preserves ulcer and malignancy risk, underscoring test-of-cure documentation.

Communication and safety nets

Patients discharged on triple therapy need written timing for each drug, clarity on what counts as an allergic reaction, and a return date for non-invasive test-of-cure. Interpreter services matter when discussing dietary myths—focus on medications and follow-up rather than unproven food restriction lists.

Escalation triggers during admission

• Systolic BP <90 mmHg or rising tachycardia after fluid boluses despite active bleeding precautions.
• Hemoglobin drop >20 g/L (2 g/dL) within 24 h without explanation.
• Altered consciousness with suspected continued blood loss.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and cloze drops on the topic of H. pylori test-of-cure timing, NSAID mucosal injury, alarm-feature escalation and PPI stewardship—mirroring the Clinical Judgment Measurement Model emphasis on prioritisation and safe action.